Alkermes
ALKS
$24.68
Share price
0.98%
Change (1 day)
-13.04%
Change (1 year)
Categories
P/S ratio for Alkermes (ALKS)
P/S ratio as of April 2024 (TTM): 2.51
According to Alkermes's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.50866. At the end of 2023 the company had a P/S ratio of 2.78.
P/S ratio history for Alkermes from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 2.78 | -27.93% |
| 2022 | 3.86 | 20.51% |
| 2021 | 3.20 | 4.84% |
| 2020 | 3.06 | 11.2% |
| 2019 | 2.75 | -34.56% |
| 2018 | 4.20 | -54.91% |
| 2017 | 9.32 | -17.75% |
| 2016 | 11.3 | -40.5% |
| 2015 | 19.0 | 36.36% |
| 2014 | 14.0 | 75.6% |
| 2013 | 7.95 | 75.93% |
| 2012 | 4.52 | -37.59% |
| 2011 | 7.24 | 7.63% |
| 2010 | 6.73 | 39.1% |
| 2009 | 4.84 | 64.83% |
| 2008 | 2.93 | -54.39% |
| 2007 | 6.43 | 9.05% |
| 2006 | 5.90 | -54.2% |
| 2005 | 12.9 | -29.98% |
| 2004 | 18.4 | -46.02% |
| 2003 | 34.1 | 298.68% |
| 2002 | 8.55 | -74.14% |
| 2001 | 33.1 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 3.79 | 50.90% | 🇺🇸 USA |
 Novartis NVS | 3.90 | 55.36% | 🇨🇭 Switzerland |
 Pfizer PFE | 2.46 | -2.03% | 🇺🇸 USA |
 Sanofi SNY | 2.44 | -2.77% | 🇫🇷 France |
 Bristol-Myers Squibb BMY | 2.02 | -19.43% | 🇺🇸 USA |
 AstraZeneca AZN | 5.09 | 102.79% | 🇬🇧 UK |
 Zogenix ZGNX | N/A | N/A | 🇺🇸 USA |
 Acorda Therapeutics
ACOR | 0.0070 | -99.72% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | 0.9871 | -60.65% | 🇮🇱 Israel |